Ocular Surface Erosion of a Vaccine for SARS-CoV2 (COVID-19 virus)

Ocular Surface Erosion after Suspected Exposure to Vaporized Solution of a Vaccine for SARS-CoV2 (COVID-19 virus)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20210510008

Enrollment

Registered

2021-05-10

Start date

2021-03-24

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy person COVID-19, Vaccine Ocular surface Cornea

Interventions

Healthcare worker who expose to vaporized solution of a vaccine for SARSCoV2 on 24 March 2021 at Rajavithi Hospital

Diagnostic

Vaccine group expose to vaporized solution of a vaccine for SARSCoV2

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Healthy person who exposure to vaporized solution of a vaccine for SARS-CoV2

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Ocular surface grading 1 week Oxford grading scale	—

Secondary

Measure	Time frame
Side effect 1 month Ocular side effect	—

Countries

Thailand

Contacts

Public ContactKasem Seresirikachorn

Rajavithi Hospital

Kasemseresiriakchorn@gmail.com0851276566

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026